Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency MIDLOTHIAN, Va., June 19, 2017 (GLOBE NEWSWIRE) -- Ammonett Pharma LLC (the Company or Ammonett), a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill...

Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope™ Related to Detecting and Treating Growth Hormone Deficiency MIDLOTHIAN, Va., May 25, 2017 (GLOBE NEWSWIRE) -- Ammonett Pharma LLC (the Company or Ammonett), a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill...

Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency MIDLOTHIAN, Va., May 23, 2017 (GLOBE NEWSWIRE) -- Ammonett Pharma LLC (the Company or Ammonett), a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill...